Navigation Links
Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
Date:9/3/2013

NEW YORK, Sept. 3, 2013 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI" or the "Company"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, announced that it completed a private placement of approximately 18.9 million shares of its common stock to new and existing investors that resulted in gross proceeds of approximately $60 million to the Company, including approximately $15.3 million in bridge notes that converted into common stock at the closing. New institutional investors included Deerfield Management, Broadfin Capital and other leading healthcare investors. Leerink Swann LLC acted as lead placement agent for the transaction, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. acted as the Company's legal counsel. Proceeds from the private placement will be used for the development of the Company's drug candidates including its lead drug candidate, ITI-007, which is being studied in a Phase II clinical trial for the treatment of schizophrenia.

Sharon Mates, CEO and Chairman of ITI, stated, "We are pleased to be able to close this private placement with such a leading group of institutional healthcare investors.  To date, ITI-007 has demonstrated clinical signs consistent with antipsychotic activity in patients with schizophrenia and its unique pharmacology may expand its therapeutic use beyond the treatment of acutely exacerbated schizophrenia to also include chronic residual schizophrenia by improving negative symptoms, mood, sleep and cognition.  We expect the proceeds from the financing will allow us to move forward with the clinical development of ITI-007 as a treatment for schizophrenia as well as other psychiatric and behavioral disorders."

Immediately following the private placement, ITI became a public reporting company by executing a reverse merger with a public shell company with no prior business operations. 
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
2. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
3. The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
4. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
5. CSL Biotherapies initiates shipments of its seasonal influenza vaccine to U.S. customers
6. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
7. The Launch of Three New Parkinsons Disease Therapies Through 2015 Will Help Offset Market Losses Resulting from the Growing Impact of Generics
8. Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
9. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
10. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
11. Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... -- IGI Laboratories, Inc. (NYSE-MKT: IG), a New Jersey ... today at the Deutsche Bank 40th Annual Health Care Conference. ... and 7 th at The InterContinental Hotel, ... CEO and President and Jenniffer Collins , Chief Financial ... 2015, at 3:30 p.m. ET.   The presentation will be ...
(Date:5/6/2015)... --  Sigma-Aldrich Corporation (NASDAQ: SIAL ) a leading ... $50,000 product donation to the Reproducibility Project: Cancer ... from recent high-impact papers in the field of cancer ... research marketplace Science Exchange , the non-profit ... eLife. The goal of the project is ...
(Date:5/6/2015)... 2015   Symbiomix Therapeutics today announced multiple ... tranche of a $41 million Series A financing and ... testing a single oral dose of SYM-1219 for the ... the U.S. Food and Drug Administration (FDA) at an ... submit the Phase 2 trial as one of two ...
Breaking Medicine Technology:Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 2Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 3Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 4Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 5
... (Nasdaq: ENDP ) announced today that it is ... of axomadol. Endo licensed exclusive rights to develop and market ... February 2009. "As a leader in the ... and commercialization of pain therapeutics," said Ivan Gergel, M.D., executive ...
... Endologix, Inc. (Nasdaq: ELGX ), developer and marketer ... Judge Tanya Walton Pratt of the United States District Court ... a Markman ruling in the ongoing patent infringement lawsuit filed ... a Markman ruling, the court determines the meaning of disputed ...
Cached Medicine Technology:Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol 2Endologix Announces Favorable Markman Ruling in Cook Patent Litigation 2
(Date:5/6/2015)... Vancouver, BC (PRWEB) May 06, 2015 ... Ace Care, has recently announced that they will now ... replacement, for strata complexes in addition to commercial and ... large scale and require a lot of technical knowledge ... “When we do an installation we will take away ...
(Date:5/6/2015)... Va. (PRWEB) May 06, 2015 ... in the state of Virginia to acquire Intuitive ... surgical robot. The system upgrade includes enhanced surgical ... minimally invasive procedures across a wide spectrum of ... options, reduced pain and quicker recovery times. , ...
(Date:5/6/2015)... Vancouver, BC (PRWEB) May 06, 2015 ... colon hydrotherapy supplier, is excited to announce a ... will help reduce the industry’s carbon footprint while ... These kits feature Eco-Flex™, the world’s ... “This is a game-changer for hydrotherapists,” claims the ...
(Date:5/6/2015)... The Beryl Institute announces the publication of ... (PXJ), an international, open access, peer-reviewed journal focused on ... experience. The second volume of PXJ supports the goal ... the voices engaged and provides the space for listening, ... The Beryl Institute, Volume 2, Issue 1 includes ...
(Date:5/6/2015)... Animals make just as good friends as they do pets. ... An Ohio veterinarian has been observing this for ... advantages of owning a pet. , “When animals and humans ... there are proven health benefits for people-- including physical, mental ... Animal Medical Center of Streetsboro said. Every May, ...
Breaking Medicine News(10 mins):Health News:Pro Ace Care Now Does Air Conditioning Installation for Strata Complexes 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 2Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 3
... Colo., Sept. 11 ,Spectranetics Corporation (Nasdaq: SPNC ... A.G. Edwards Growth Conference, which is being held,September ... John G. Schulte, Spectranetics, president and chief executive ... at 9:30 a.m. Eastern time,(7:30 a.m. Mountain time) ...
... Board of Directors of,Bristol-Myers Squibb Company (NYSE: BMY ... per share on the $.10 par value,Common Stock of ... 1, 2007 to stockholders of record at the close ... declared a quarterly dividend of fifty cents ($0.50),per share ...
... Sept. 11 Washington state nursing,leader Sally Watkins, ... of,Nursing Practice, Education, and Research by the Washington ... professional nurses,association and union. "We are very ... leader,who will be a strong patient and nurse ...
... nuclear power industry is riding the green wave back ... solution to our growing energy needs. But even as ... realistically play, it is bound by a global energy ... by the marketplace. , Veteran New York Times ...
... a third of prostate biopsies resulted in a cancer ... Men whose first biopsy did not find cancer often ... chance of a cancer diagnosis. , While PSA ... cancer screening, a biopsy is what actually determines the ...
... at the University of Oregon and requiring no more ... after a doctors appointment is credited with a 224-percent ... mild developmental delays in a yearlong study. , Researchers ... referrals for special services or additional monitoring would not ...
Cached Medicine News:Health News:Spectranetics to Present at The A.G Edwards Growth Conference on September 18 2Health News:New Director of Nursing Practice Named for Nurses Association 2Health News:Trade-offs reveal no clear favorites in alternative energy market 2Health News:Other highlights in the September 11 JNCI 2Health News:Other highlights in the September 11 JNCI 3Health News:Parental surveys boost diagnosis abilities of pediatricians 2Health News:Parental surveys boost diagnosis abilities of pediatricians 3
... Sterile E*Kits® can be a valuable ... care; when the items necessary for a ... facility protocols and continuum of care are ... are packaged in sequence of use, allowing ...
... trays to dry trays to specialty vaginal ... Cardinal Health offers the widest offering in ... components that are proven to be safe ... of surgical site infections. Cardinal Health Scrub ...
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... Panel consists of plasma specimens with reactivity ... antibodies to HTLV I and II. This ... and diagnostic laboratories to evaluate their anti-HTLV ... test systems are included for comparative analysis ...
Medicine Products: